In line with our vision, Atturos is committed to developing tests that allow patients and clinicians to make better decisions based on excellent science.
RAPsA Dx is Atturos' lead product. With its ability to discriminate patients who have rheumatoid arthritis (RA) from those who have psoriatic arthritis (PsA) it is the first molecular diagnostic test (Dx) for the diagnosis of psoriatic arthritis.
The RAPsA Dx test performance of over 90% has been fully evaluated and is described in a recent landmark peer reviewed publication.
The RAPsA Dx protein signature is the subject of a patent from University College Dublin (UCD) and is licenced exclusively to Atturos worldwide.
OCPro Dx is a multi-protein biomarker blood test for organ confined prostate cancer that gives patients and clinicians clearer information to help them make treatment decisions. Early clinical data supports the continued commercialisation of the product. Atturos is currently assessing plans to commercialise the development strategy for OCPro Dx.